Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Beysens AJ et al. | FK 506: monitoring in plasma or in whole blood? | 1991 | Transplant. Proc. | pmid:1721263 |
Grenier FC et al. | A whole blood FK 506 assay for the IMx analyzer. | 1991 | Transplant. Proc. | pmid:1721264 |
Friob MC et al. | A combined HPLC-ELISA evaluation of FK 506 in transplant patients. | 1991 | Transplant. Proc. | pmid:1721265 |
Machida M et al. | Effect of temperature and hematocrit on plasma concentration of FK 506. | 1991 | Transplant. Proc. | pmid:1721266 |
Bierer BE et al. | FK 506 and rapamycin: molecular probes of T-lymphocyte activation. | 1991 | Transplant. Proc. | pmid:1721296 |
Tanida I et al. | Yeast cyclophilin-related gene encodes a nonessential second peptidyl-prolyl cis-trans isomerase associated with the secretory pathway. | 1991 | Transplant. Proc. | pmid:1721297 |
O'Neill EA et al. | The FK 506-sensitive nature of the interleukin-2 promoter is derived from a specific array of multiple regulatory elements. | 1991 | Transplant. Proc. | pmid:1721298 |
Nelson PA et al. | Effect of immunosuppressive drugs on cytokine gene transcription studied by message amplification phenotyping (MAPPing) polymerase chain reaction. | 1991 | Transplant. Proc. | pmid:1721299 |
Hultsch T and Hohman RJ | Categorizing receptor-signaling pathways with FK 506 and rapamycin. | 1991 | Transplant. Proc. | pmid:1721328 |
Takai K et al. | Immunosuppressive effects of FK 506 on rat lymphoid organs. | 1991 | Transplant. Proc. | pmid:1721329 |
Ishibashi M et al. | Effect of FK 506 on generation of activated macrophages invading rejected skin allografts in rats: discrepancy of in vitro versus in vivo effects. | 1991 | Transplant. Proc. | pmid:1721330 |
Kawauchi M et al. | Flow cytometric analysis of lymphocyte populations in FK 506-treated newborn goats. | 1991 | Transplant. Proc. | pmid:1721331 |
Dew MA et al. | Quality-of-life advantages of FK 506 vs conventional immunosuppressive drug therapy in cardiac transplantation. | 1991 | Transplant. Proc. | pmid:1721360 |
Gordon RD et al. | Liver transplantation under cyclosporine: a decade of experience. | 1991 | Transplant. Proc. | pmid:1703339 |
Shapiro R et al. | FK 506 in clinical kidney transplantation. | 1991 | Transplant. Proc. | pmid:1721361 |
Todo S et al. | One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. | 1991 | Transplant. Proc. | pmid:1703340 |
McCauley J et al. | Renal transplantation under FK 506 in patients with previous loss of renal function due to hemolytic uremic syndrome. | 1991 | Transplant. Proc. | pmid:1721362 |
Zeevi A et al. | Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection. | 1991 | Transplant. Proc. | pmid:1703341 |
Japanese study of FK 506 on kidney transplantation: results of an early phase II study. Japanese FK 506 Study Group. | 1991 | Transplant. Proc. | pmid:1721363 | |
van Hoek B et al. | Recurrence of ductopenic rejection in liver allografts after retransplantation for vanishing bile duct syndrome. | 1991 | Transplant. Proc. | pmid:1703343 |
Rilo HL et al. | Effect of FK 506 on function of human islets of Langerhans. | 1991 | Transplant. Proc. | pmid:1721393 |
Carroll PB et al. | Synexin: a target protein for toxic effects of cyclosporine and FK 506 in endocrine cells. | 1991 | Transplant. Proc. | pmid:1721394 |
Scantlebury V et al. | New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. | 1991 | Transplant. Proc. | pmid:1721395 |
Carroll PB et al. | FK 506-associated diabetes mellitus in the pediatric transplant population is a rare complication. | 1991 | Transplant. Proc. | pmid:1721396 |
Yoshimi F et al. | Canine total orthotopic small bowel transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721422 |
Santiago SF et al. | Effect of donor pretreatment with FK 506 upon small intestine allotransplantation in rats. | 1991 | Transplant. Proc. | pmid:1721423 |
Murase N et al. | Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. | 1991 | Transplant. Proc. | pmid:1721424 |
Langrehr JM et al. | Indefinite small bowel allograft survival after limited immunosuppressive therapy is not due to specific hyporesponsiveness. | 1991 | Transplant. Proc. | pmid:1721425 |
de Paulis A et al. | FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. | 1991 | J. Immunol. | pmid:1706398 |
Griffiths EJ and Halestrap AP | Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin. | 1991 | Biochem. J. | pmid:1706598 |
Brabletz T et al. | The immunosuppressives FK 506 and cyclosporin A inhibit the generation of protein factors binding to the two purine boxes of the interleukin 2 enhancer. | 1991 | Nucleic Acids Res. | pmid:1707162 |
Iwaki Y et al. | Replacement of donor lymphoid tissue in small-bowel transplants. | 1991 | Lancet | pmid:1707470 |
Liversidge J et al. | FK 506 modulates accessory cell adhesion molecule expression and inhibits CD4 lymphocyte adhesion to retinal pigment epithelial cells in vitro: implications for therapy of uveoretinitis. | 1991 | Transplant. Proc. | pmid:1721455 |
Mochizuki M et al. | A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease. Japanese FK 506 Study Group on Refractory Uveitis. | 1991 | Transplant. Proc. | pmid:1721456 |
Roat MI et al. | Treatment of Cogan's syndrome with FK 506: a case report. | 1991 | Transplant. Proc. | pmid:1721457 |
Carroll PB et al. | The use of FK 506 in new-onset type I diabetes in man. | 1991 | Transplant. Proc. | pmid:1721458 |
McAlpine JB et al. | Revised NMR assignments for rapamycin. | 1991 | J. Antibiot. | pmid:1712766 |
Banerji SS et al. | The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. | 1991 | Mol. Cell. Biol. | pmid:1712901 |
Markus PM et al. | FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. | 1991 | Surgery | pmid:1713358 |
Farley DE et al. | The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. | 1991 | Transplantation | pmid:1713360 |
Sakr MF et al. | Protective effect of FK 506 against hepatic ischemia in rats. | 1991 | Transplant. Proc. | pmid:1703689 |
Katayama Y et al. | Immunosuppressive effects of FK 506 and 15-deoxyspergualin in rat lung transplantation. | 1991 | Transplant. Proc. | pmid:1703690 |
Thomson AW | The immunosuppressive macrolides FK-506 and rapamycin. | 1991 | Immunol. Lett. | pmid:1717376 |
Takaya S et al. | Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1703691 |
Nakahama H et al. | Comparative effects of cyclosporine A and FK-506 on endothelin secretion by a cultured renal cell line, LLC-PK1. | 1991 | J. Cardiovasc. Pharmacol. | pmid:1725322 |
Steeves M et al. | In-vitro interaction of a novel immunosuppressant, FK 506, and antacids. | 1991 | J. Pharm. Pharmacol. | pmid:1717676 |
Hildebrandt A et al. | FK 506: short- and long-term treatment after cardiac transplantation in nonhuman primates. | 1991 | Transplant. Proc. | pmid:1703694 |
Romanowski P et al. | [Synthetic immunomodulators designed on the basis of natural products of microorganisms]. | 1991 | Postepy Biochem. | pmid:1725924 |
Altmeyer A et al. | Unexpected up-regulation of gene expression by cyclosporin A and FK-506 in a T-cell lymphoma: both immunosuppressants augment Ly-6E antigen induction by interferon-gamma in the presence of ionomycin. | 1991 | Int. J. Immunopharmacol. | pmid:1726093 |
Gordon RD et al. | Liver transplantation at the University of Pittsburgh, 1984 to 1990. | 1991 | Clin Transpl | pmid:1726458 |